Recently, Prof. Chen Xiaoyuan, Nasrat Muzayyin Chair Professor in Medicine and Technology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Prof. Huang Gang, President of the Shanghai University of Medicine & Health Sciences, and other well-known experts and professors visited Yantai to analyze new trends in the future development of the nuclear medicine industry and jointly seek the rapid development of Yantai's nuclear medicine industry.

Policy Guidance with Right Timing

Promoting the high-quality development of medical isotopes is of great significance for promoting the construction of China’s health system. After the joint release of the “Medium - and Long Term Development Plan for Medical Isotopes (2021-2035)” by eight ministries and commissions, in 2022, the Yantai Municipal Government released China's first urban medical isotope industry plan - the Yantai Medical Isotope Health Industry Development Plan, focusing on cultivating and developing the medical isotope health industry, and taking the lead in achieving localized supply of medical isotopes nationwide. According to the planning goals, by 2035, the entire medical isotope industry chain in Yantai will achieve high-level self-reliance and self-improvement, and build an industrial ecosystem with global influence. From national strategy to policy guidance, it has pointed out the direction for the development of the nuclear medicine industry.

Prof. Chen Xiaoyuan was appointed as "Yantai Expert Advisory Committee and 'Yantai Biomedical Industry Think Tank' Invited Expert in the Field of Pharmaceutical Isotopes".

Build Leading Enterprise with Geographical Advantage

Prof. Huang Gang commented on Yantai's medical isotopes industry: “Yantai has unique characteristics in the development of China's radiopharmaceutical industry”. At present, Yantai, which is fully committed to developing the biopharmaceutical industry, is accumulating development on the high ground of the medical isotope industry. The International Pharmaceutical Innovation Application Project located in Muping District is attracting the first batch of 10 projects from DC PHARMA as the main attraction and pillar, and is committed to creating an internationally leading nuclear medicine industry cluster integrating domestic independent production, independent R&D, and independent management. As one of the leading nuclear medicine enterprises in China, DC PHARMA relies on its first mover advantage in the entire nuclear medicine industry chain and is steadily promoting the landing of the medical isotope production system, jointly creating the "New Business Card of Yantai Nuclear Medicine".

Innovation is the core element driving the development of China's nuclear medicine industry to reach the international advanced levels. As a world-class expert in the field of molecular imaging and nanomedicine, Prof. Chen Xiaoyuan has always been his unremitting pursuit to combine the world’s leading nuclear medicine technology with the industry to benefit patients.

Prof. Chen Xiaoyuan and DC PHARMA's R&D team had in-depth discussions on project implementation and R&D breakthroughs.

Prof. Chen Xiaoyuan gave a nuclear medicine keynote report at Yantai Yuhuangding Hospital

Prof. Chen Xiaoyuan had academic exchanges with Mr. Sun Chengming, Vice President, Mr. Li Shanchun, Director, and many other colleagues

At the beginning of 2021, Prof. Chen Xiaoyuan and DC PHARMA jointly established LNC, relying on the patented technology of Evans Blue, dedicated to the R&D of radiotheranostic medicine. This is a completely independent R&D platform innovated by DC PHARMA. It is also an important project in the DC PHARMA nuclear medicine ecosystem, with top R&D strength, strong R&D momentum, and broad development space.

LNC1004等均获批进入 I 期临床试验，在新药研发上跑出了“东诚速度”。

In just two years, LNC’s first innovative radionuclide drugs, 18F-LNC1001 Injection for prostate cancer diagnosis, 18F-LNC1005 Injection for gastric cancer diagnosis, and 177Lu-LNC1004 Injection for oncology therapy, have all been approved to enter phase I clinical trials, all of which have achieved "DC PHARMA Speeds" in the research and development of new drugs.

R&D Milestones of LNC

Jul. 2022

18F-LNC1001 Injection, LNC’s first innovative nuclear drug for prostate cancer diagnosis, , has obtained the IND approval from the NMPA, and officially entered the phase I clinical trial stage.

Dec. 2022

18F-LNC1005 injection, LNC’S innovative nuclear drug for gastric cancer diagnosis, has obtained the IND approval from the NMPA. There are currently no therapeutic or diagnostic drugs with the same target on the market or under development in China.

Dec. 2022

LNC PHARMA has received the FDA IND approval for the 68Ga-FAPI46 injection as the companion diagnostic drug, which is used for patient screening, efficacy evaluation, and collection of relevant safety information.

Jan. 2023

LNC PHARMA received the IND approval from the US FDA regarding the 177Lu-LNC1004 injection for Phase I clinical trial.

Regarding the future of LNC, Prof. Chen Xiaoyuan stated, "We still need to continuously increase our R&D efforts to improve our R&D speed, strive to promote Chinese radiopharmaceuticals to the world, and strive to play a leading role in the global radiopharmaceutical industries, so that more people can benefit from precision therapy."

In Yantai, a beautiful coastal city, under the support of DC PHARMA’s complete nuclear medicine ecosystem, the regional advantages for the whole isotope industry chain to achieve high-level and self-reliance goals in the isotope industry chain has been created.

Talent Gathering with Cooperation

Recently, a special ceremony was held at DC PHARMA. Prof. Huang Gang, the Director of the Shanghai Molecular Imaging Key Laboratory and the Doctoral Supervisor at Shanghai Jiao Tong University School of Medicine, was appointed as an expert consultant, and will engage in in-depth cooperation with DC PHARMA in drug innovation R&D, talent training, and other aspects.

Prof. Huang Gang introduced that the value of nuclear medicine in clinical diagnosis is very unique, especially in the early diagnosis and treatment of tumors. With the aging population, the market demand for nuclear drugs will increase, and the clinical value will also be further highlighted. "This also puts higher demands on radiopharmaceuticals companies, not only in R&D, but more importantly, in talent training, application of transformation, and cooperation with medical institutions, to leverage the power of enterprises and provide support."

Professor Huang Gang

At present, DC PHARMA has gathered numerous top scientists over the world led by Prof. Chen Xiaoyuan, Prof. Lei Pingsheng, Academician Zhao Xiangeng, Academician Wang Rui, Academician Jiang Jiandong, Academician Deng Jianjun, Prof. Huang Gang, and Prof. Du Yong, as well as a large number of backbone strength dedicated to DC PHARMA's R&D, injecting strong driving force into DC PHARMA's innovative development. The plans such as "State Key Laboratory of Nuclear Medicine and Natural Medicine", "Cooperative Academician Experiment Center", "The Heavy Water Reactor and the Cyclotron Project Construction". With the development of more and more professional innovation and R&D cooperation, and batches of "new youths" with ideas and enthusiasm are pouring into Yantai, to seek common development of the nuclear medicine industry.

With the guidance and support of the government, the efforts of leading enterprises in the industry, and the gathering of numerous experts and talents, as Prof. Chen Xiaoyuan said, the development of Yantai's nuclear medicine industry has the conditions of “right timing, location and cooperation”. DC PHARMA will also contribute to the great development of China's nuclear medicine industry and the takeoff of Yantai's nuclear medicine industry.